-
1
Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab
Published 2025-01-01Subjects: Get full text
Article -
2
Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer
Published 2025-01-01Subjects: “…Bispecific T-cell engager…”
Get full text
Article -
3